Skip to main content
main-content

ALK fusion-positive NSCLC: International approaches to management

Current options for the detection and treatment of ALK fusion-positive NSCLC


Ross Camidge leads Rosario García Campelo and Yongchang Zhang in a discussion on the detection and treatment of ALK fusion-positive NSCLC in current practice.

Transcript


Please feedback

Thank you for watching, please take a moment complete our short survey.

Meet the faculty

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

Faculty disclosures

Faculty disclosures

Ross Camidge

Advisory role: Ad hoc advisory boards/consultations

2022: Appolomics (SRC),  AstraZeneca/Daiichi (ILD adjudication committee), Beigene (DSMB) EMD Serono, Medtronic, Mersana (ILD adjudication committee), Mirati, Onkure, Roche

2021: Abbvie, Amgen, Anheart, Apollomics (SRC), AstraZeneca (SRC/SC), Beigene (DSMC), Bio-Thera (DSMB), Blueprint, Daiichi-Sankyo (ILD adjudication committee), Elevation (SRC), Eli Lilly (DSMB and NCCN), EMD Serono, Helsinn (DSMB), Hengrui (DSMC), Janssen, Kestrel (SAB, Shares), Mersana, Nuvalent (SAB), Puma (NCCN), Ribon, Roche/Genentech, Sanofi, Seattle Genetics, Takeda, Turning Point

2020: Amgen, Anchiarno (SAB), Apollomics (SRC), AstraZeneca, Bio-Thera (DSMB), BMS, Daiichi-Sankyo (ILD adjudication committee), Eisai, EMD Serono, Elevation (SRC), Eli Lilly, GSK, Helssin, Janssen, Onkure, Mersana, Pfizer, Qilu, Roche, Sanofi, Seattle Genetics, Takeda

Research funding

Inivata

Company sponsored trials at institution (PI roles)

2020-22: Abbvie, AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point, Verastem

Rosario García Campelo

Advisory boards

 MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda

Consultancy

MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda

Speaker honoraria

MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda

Yongchang Zhang

Declares no conflict of interest

Funding and disclaimer

Funding and disclaimer

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited, Springer Nature Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Attention: This content is intended for healthcare professionals only

In order to proceed please confirm whether you are a healthcare professional.

No, I am not a
healthcare professional
Yes, I am a
healthcare professional